Regulatory filings, facility milestones, and where to find the BioTicha team next.
Our finished formulation injectable facility has added capacity for oncology and antiviral programmes, from early formulation through scale up and stability.
Our sterile fill finish suite completed WHO-GMP re certification with zero critical findings, maintaining an unbroken inspection record across the site.
A territory exclusive licensing arrangement brings four finished dosage programmes to a regional distribution partner across the Middle East and North Africa.
The additional chamber increases freeze dried batch throughput for the European hub while retaining full EU-GMP qualification.
Registration in three new territories brings the active supply network to thirty markets across Europe, Asia, and the MENA region.